• AstraZeneca's Farxiga pads its case for new heart-helping approval fiercepharma
    August 22, 2019
    AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease. But here's something that could ease the pain: New outcomes data showing Farxiga cut cardiovascular risks in heart failure patients—with or wit
PharmaSources Customer Service